Published in Chest on May 14, 2010
Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin Microbiol Rev (2011) 2.23
Polymicrobial interactions: impact on pathogenesis and human disease. Clin Microbiol Rev (2012) 2.14
The airway microbiota in cystic fibrosis: a complex fungal and bacterial community--implications for therapeutic management. PLoS One (2012) 1.80
Control of Candida albicans metabolism and biofilm formation by Pseudomonas aeruginosa phenazines. MBio (2013) 1.18
Characterization and quantification of the fungal microbiome in serial samples from individuals with cystic fibrosis. Microbiome (2014) 1.05
Candida albicans-produced farnesol stimulates Pseudomonas quinolone signal production in LasR-defective Pseudomonas aeruginosa strains. Microbiology (2010) 1.03
Antifungal mechanisms by which a novel Pseudomonas aeruginosa phenazine toxin kills Candida albicans in biofilms. Mol Microbiol (2010) 1.02
Long-Term Evolution of Burkholderia multivorans during a Chronic Cystic Fibrosis Infection Reveals Shifting Forces of Selection. mSystems (2016) 1.01
The lung mycobiome: an emerging field of the human respiratory microbiome. Front Microbiol (2015) 0.97
The basidiomycetous yeast Trichosporon may cause severe lung exacerbation in cystic fibrosis patients - clinical analysis of Trichosporon positive patients in a Munich cohort. BMC Pulm Med (2013) 0.96
Candida albicans ethanol stimulates Pseudomonas aeruginosa WspR-controlled biofilm formation as part of a cyclic relationship involving phenazines. PLoS Pathog (2014) 0.93
Cystic Fibrosis Lung Infections: Polymicrobial, Complex, and Hard to Treat. PLoS Pathog (2015) 0.87
Changes in cystic fibrosis airway microbial community associated with a severe decline in lung function. PLoS One (2015) 0.84
Update on host-pathogen interactions in cystic fibrosis lung disease. Mol Cell Pediatr (2016) 0.81
Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset. Expert Rev Mol Diagn (2011) 0.81
Global Analysis of the Fungal Microbiome in Cystic Fibrosis Patients Reveals Loss of Function of the Transcriptional Repressor Nrg1 as a Mechanism of Pathogen Adaptation. PLoS Pathog (2015) 0.80
Applying Convergent Immunity to Innovative Vaccines Targeting Staphylococcus aureus. Front Immunol (2014) 0.78
A Multifaceted Study of Scedosporium boydii Cell Wall Changes during Germination and Identification of GPI-Anchored Proteins. PLoS One (2015) 0.76
Chronic candidal bronchitis: a consecutive series. Open Respir Med J (2012) 0.75
Long-Term Rasamsonia argillacea Complex Species Colonization Revealed by PCR Amplification of Repetitive DNA Sequences in Cystic Fibrosis Patients. J Clin Microbiol (2016) 0.75
Pathogenesis of Fungal Infections in Cystic Fibrosis. Curr Fungal Infect Rep (2016) 0.75
Persistence of Candida dubliniensis and lung function in patients with cystic fibrosis. BMC Res Notes (2017) 0.75
Early discontinuation of tamoxifen: a lesson for oncologists. Cancer (2007) 3.12
Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol (2011) 2.99
Modelling the decreasing coronary heart disease mortality in Sweden between 1986 and 2002. Eur Heart J (2009) 2.89
Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results. Hum Gene Ther (2011) 2.75
Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis. Am J Respir Crit Care Med (2011) 2.37
Clarification of the risk of chronic obstructive pulmonary disease in α1-antitrypsin deficiency PiMZ heterozygotes. Am J Respir Crit Care Med (2014) 2.14
Potentially inappropriate prescribing and cost outcomes for older people: a national population study. Br J Clin Pharmacol (2010) 2.04
Effect of estrogen on pseudomonas mucoidy and exacerbations in cystic fibrosis. N Engl J Med (2012) 1.93
Z alpha1-antitrypsin polymerizes in the lung and acts as a neutrophil chemoattractant. Chest (2004) 1.88
Anti-proline-glycine-proline or antielastin autoantibodies are not evident in chronic inflammatory lung disease. Am J Respir Crit Care Med (2009) 1.86
Assessment of arterial stiffness in hypertension: comparison of oscillometric (Arteriograph), piezoelectronic (Complior) and tonometric (SphygmoCor) techniques. J Hypertens (2009) 1.78
Decline in mortality from coronary heart disease in Poland after socioeconomic transformation: modelling study. BMJ (2012) 1.69
TLR-induced inflammation in cystic fibrosis and non-cystic fibrosis airway epithelial cells. J Immunol (2005) 1.67
Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding. J Exp Med (2005) 1.65
Endotoxin up-regulates interleukin-18: potential role for gram-negative colonization in sarcoidosis. Am J Respir Crit Care Med (2005) 1.57
Health impacts of increasing alcohol prices in the European Union: a dynamic projection. Prev Med (2012) 1.55
Activation of endoplasmic reticulum-specific stress responses associated with the conformational disease Z alpha 1-antitrypsin deficiency. J Immunol (2004) 1.53
Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination. J Biol Chem (2002) 1.52
Explaining the decrease in coronary heart disease mortality in Italy between 1980 and 2000. Am J Public Health (2009) 1.51
Alpha-1 antitrypsin deficiency. Respir Med (2010) 1.51
Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1α. Mol Cell (2011) 1.48
miR-199a-5p silencing regulates the unfolded protein response in chronic obstructive pulmonary disease and α1-antitrypsin deficiency. Am J Respir Crit Care Med (2014) 1.46
Emergency medical readmission: long-term trends and impact on mortality. Clin Med (2011) 1.46
α1-Antitrypsin activates protein phosphatase 2A to counter lung inflammatory responses. Am J Respir Crit Care Med (2014) 1.45
miR-31 dysregulation in cystic fibrosis airways contributes to increased pulmonary cathepsin S production. Am J Respir Crit Care Med (2014) 1.45
Extubation versus tracheostomy in withdrawal of treatment-ethical, clinical, and legal perspectives. J Crit Care (2009) 1.44
Potentially inappropriate prescribing and cost outcomes for older people: a cross-sectional study using the Northern Ireland Enhanced Prescribing Database. Eur J Clin Pharmacol (2012) 1.40
Adult-onset nemaline myopathy presenting as respiratory failure. Respir Care (2008) 1.40
Neutrophil elastase up-regulates interleukin-8 via toll-like receptor 4. FEBS Lett (2003) 1.38
α-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. J Clin Invest (2010) 1.38
miR-126 is downregulated in cystic fibrosis airway epithelial cells and regulates TOM1 expression. J Immunol (2010) 1.38
Prevalence of chronic disease in the elderly based on a national pharmacy claims database. Age Ageing (2006) 1.35
Analysing the large decline in coronary heart disease mortality in the Icelandic population aged 25-74 between the years 1981 and 2006. PLoS One (2010) 1.32
Epithelial expression of TLR4 is modulated in COPD and by steroids, salmeterol and cigarette smoke. Respir Res (2007) 1.31
Loss of microbicidal activity and increased formation of biofilm due to decreased lactoferrin activity in patients with cystic fibrosis. J Infect Dis (2004) 1.25
MicroRNAs in inflammatory lung disease--master regulators or target practice? Respir Res (2010) 1.24
Inactivation of human beta-defensins 2 and 3 by elastolytic cathepsins. J Immunol (2003) 1.24
Choice of first antihypertensive--are existing guidelines ignored? Br J Clin Pharmacol (2007) 1.24
Evidence for an age and gender bias in the secondary prevention of ischaemic heart disease in primary care. Br J Clin Pharmacol (2003) 1.24
LL-37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hypertonic saline. J Immunol (2009) 1.22
Activation of the epidermal growth factor receptor (EGFR) by a novel metalloprotease pathway. J Biol Chem (2008) 1.20
Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. J Clin Invest (2013) 1.20
Secretory leucoprotease inhibitor impairs Toll-like receptor 2- and 4-mediated responses in monocytic cells. Infect Immun (2004) 1.20
Supporting the improvement and management of prescribing for urinary tract infections (SIMPle): protocol for a cluster randomized trial. Trials (2013) 1.19
Statins and risk of treated incident diabetes in a primary care population. Br J Clin Pharmacol (2013) 1.18
Proteases and antiproteases in chronic neutrophilic lung disease - relevance to drug discovery. Br J Pharmacol (2009) 1.18
Antimicrobial proteins and polypeptides in pulmonary innate defence. Respir Res (2006) 1.18
Elastolytic proteases: inflammation resolution and dysregulation in chronic infective lung disease. Am J Respir Crit Care Med (2005) 1.18
Neutrophil elastase up-regulates cathepsin B and matrix metalloprotease-2 expression. J Immunol (2007) 1.17
Antimicrobial management and appropriateness of treatment of urinary tract infection in general practice in Ireland. BMC Fam Pract (2011) 1.14
Trimethoprim and ciprofloxacin resistance and prescribing in urinary tract infection associated with Escherichia coli: a multilevel model. J Antimicrob Chemother (2012) 1.13
Risk prediction models to predict emergency hospital admission in community-dwelling adults: a systematic review. Med Care (2014) 1.11
Comparison of tobacco control scenarios: quantifying estimates of long-term health impact using the DYNAMO-HIA modeling tool. PLoS One (2012) 1.11
Potentially inappropriate prescribing and adverse health outcomes in community dwelling older patients. Br J Clin Pharmacol (2014) 1.11
Amnesia for loss of consciousness is common in vasovagal syncope. Europace (2011) 1.10
Toll-like receptor expression and function in airway epithelial cells. Arch Immunol Ther Exp (Warsz) (2005) 1.09
A cohort study of metformin exposure and survival in patients with stage I-III colorectal cancer. Cancer Epidemiol Biomarkers Prev (2013) 1.08
17Beta-estradiol inhibits IL-8 in cystic fibrosis by up-regulating secretory leucoprotease inhibitor. Am J Respir Crit Care Med (2010) 1.08
A RCT evaluating the effectiveness and cost-effectiveness of academic detailing versus postal prescribing feedback in changing GP antibiotic prescribing. J Eval Clin Pract (2009) 1.08
Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation. J Immunol (2009) 1.07
A review of studies of adherence with antihypertensive drugs using prescription databases. Ther Clin Risk Manag (2005) 1.07
Cytosolic pH and the inflammatory microenvironment modulate cell death in human neutrophils after phagocytosis. Blood (2002) 1.06
Evidence for unfolded protein response activation in monocytes from individuals with alpha-1 antitrypsin deficiency. J Immunol (2010) 1.05
Elafin, an elastase-specific inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with cystic fibrosis. J Biol Chem (2008) 1.03
Prevalence of potentially inappropriate prescribing and prescribing omissions in older Irish adults: findings from The Irish LongituDinal Study on Ageing study (TILDA). Eur J Clin Pharmacol (2014) 1.02
A multilevel analysis of trimethoprim and ciprofloxacin prescribing and resistance of uropathogenic Escherichia coli in general practice. J Antimicrob Chemother (2010) 1.01
Agreement between patient interview data on prescription medication use and pharmacy records in those aged older than 50 years varied by therapeutic group and reporting of indicated health conditions. J Clin Epidemiol (2013) 1.01
Selenoprotein S/SEPS1 modifies endoplasmic reticulum stress in Z variant alpha1-antitrypsin deficiency. J Biol Chem (2009) 1.01
Targeting neutrophil elastase in cystic fibrosis. Expert Opin Ther Targets (2008) 1.00
Influence of socioeconomic status on the quality of prescribing in the elderly -- a population based study. Br J Clin Pharmacol (2004) 1.00
Elafin prevents lipopolysaccharide-induced AP-1 and NF-kappaB activation via an effect on the ubiquitin-proteasome pathway. J Biol Chem (2006) 1.00
Modelling Coronary Heart Disease Mortality declines in the Republic of Ireland, 1985-2006. Int J Cardiol (2013) 1.00
Opt-out as an acceptable method of obtaining consent in medical research: a short report. BMC Med Res Methodol (2011) 1.00